You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

38 search results for: CRSwNP

expert video

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

29 min

Pulmonology

Join global experts for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in <b>CRSwNP</b>?

expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

5 min

Rhinology

Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission

What contributes more to loss of smell in patients with <b>CRSwNP</b>: nasal obstruction or inflammation?

expert video

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

5 min

Rhinology

Prof. Mullol discusses the contribution of nasal obstruction and inflammation in loss of smell in patients with CRSwNP

Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

15 min

Rhinology

Profs. Wytske Fokkens and Joaquim Mullol discuss the clinical significance of the loss of smell in patients with CRSwNP.

Podcast

ADVENT On Air | Remission in CRSwNP

19 min

Rhinology

Prof. Peter Hellings and Dr. Stella Lee discuss the concept of remission for patients with chronic rhinosinusitis with nasal polyps.

Partnering With Patients: Scores That Matter in <b>CRSwNP</b>

interactivity

Partnering With Patients: Scores That Matter in CRSwNP

5 min

Rhinology

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent <b>CRSwNP</b>

expert video

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

9 min

Rhinology

Prof. Joaquim Mullol reports on biologic improvements in sense of smell and nasal congestion in patients with and without a history of endoscopic sinus surgery.

When is the right time to consider a biologic in patients with <b>CRSwNP</b>?

expert video

When is the right time to consider a biologic in patients with CRSwNP?

5 min

Rhinology

Prof. Hellings and Prof. Corso explain that the right time to implement a biologic depends on academic and reimbursement criteria, which vary by country.

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, <b>CRSwNP</b>, and EoE

Infographic

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

5 min

Type 2 Inflammation

Discover how barrier dysfunction, neuroimmune dysregulation, and type 2 inflammation contribute to the pathophysiology of various diseases

expert video

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

2 min

Rhinology

This video clip from the EAACI 2024 symposium highlights that a multidisciplinary approach is essential for the treatment of asthma.

videoanimation

Type 2 Inflammation as the Common Thread in Multiple Diseases

5 min

Type 2 Inflammation

This video highlights type 2 inflammation as the common thread that links AD, asthma, CRSwNP, and EoE.

expert video

How does a decrease in smell affect sleep disturbance? Is there any direct relation?

5 min

Rhinology

Prof. Mullol share his opinion on connection between loss of smell and sleep disorder in patients with CRSwNP.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region